Cooney Erin E, Yeh Ping Teresa, Kennedy Katrina S, Kaptchuk Rose Pollard, Wong Brooke, Kennedy Caitlin E
Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
Department of Health, Behavior and Society, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
EClinicalMedicine. 2025 Aug 30;88:103460. doi: 10.1016/j.eclinm.2025.103460. eCollection 2025 Oct.
Many transgender and gender-diverse individuals take gender-affirming hormones, but the evidence for their impact on health and wellbeing has not been comprehensively synthesized.
We conducted a systematic review of studies reporting health and quality of life outcomes, values and preferences, and costs associated with gender-affirming hormones. The protocol was prospectively registered in PROSPERO (CRD42024451558). We searched PubMed, Embase, CINAHL, Cochrane Central, LILACS, PsycINFO, and grey literature sources for relevant evidence published between 1 January 2013 and 31 March 2024, without language or geographical restrictions. The health and quality of life outcomes review included data from randomized controlled trials (RCT) and longitudinal studies that compared adults (age 18+) who received gender-affirming hormones within the health sector to those who did not but expressed a desire to receive such care. We synthesized outcomes data using GRADE evidence profiles and assessed risk of bias with Cochrane ROB2 and ROBINS-I. We qualitatively summarized findings on values and preferences and cost, and provided confidence ratings using GRADE CERQual.
Thirteen studies, including one RCT and 12 longitudinal studies, were included in the health and quality of life outcomes review. Data from the RCT was judged to be low-certainty evidence. Uncontrolled longitudinal studies had serious to critical risk of bias. Findings from these studies suggest gender-affirming hormones may improve outcomes including depression, quality of life, and suicidality. No studies identified substantive harms. We identified an additional 17 studies on values and preferences and one study presenting cost data; data suggest that gender-affirming hormones are acceptable and affordable.
Available evidence indicates gender-affirming hormones may improve critical outcomes, including mental health and quality of life, with no evidence of substantive harms. Further evidence from prospective, controlled studies could improve the confidence in these findings.
World Health Organization through a grant from the Elton John AIDS Foundation and the Bill and Melinda Gates Foundation.
许多跨性别和性别多样化的个体使用性别确认激素,但关于其对健康和幸福影响的证据尚未得到全面综合。
我们对报告性别确认激素相关的健康和生活质量结果、价值观和偏好以及成本的研究进行了系统综述。该方案已在国际前瞻性系统评价注册库(PROSPERO,注册号:CRD42024451558)中预先注册。我们检索了PubMed、Embase、护理学与健康领域数据库(CINAHL)、Cochrane中心对照试验注册库、拉丁美洲及加勒比卫生科学数据库(LILACS)、心理学文摘数据库(PsycINFO)以及灰色文献来源,以获取2013年1月1日至2024年3月31日期间发表的相关证据,无语言或地域限制。健康和生活质量结果综述纳入了来自随机对照试验(RCT)和纵向研究的数据,这些研究比较了在卫生部门接受性别确认激素治疗的成年人(18岁及以上)与未接受但表示希望接受此类治疗的成年人。我们使用GRADE证据概要综合结果数据,并使用Cochrane偏倚风险评估工具2(ROB2)和观察性研究的偏倚风险评估工具(ROBINS - I)评估偏倚风险。我们对关于价值观和偏好以及成本的研究结果进行了定性总结,并使用GRADE证据可信度评估工具(CERQual)提供可信度评级。
健康和生活质量结果综述纳入了13项研究,包括1项RCT和12项纵向研究。RCT的数据被判定为低确定性证据。非对照纵向研究存在严重至关键的偏倚风险。这些研究的结果表明,性别确认激素可能改善包括抑郁、生活质量和自杀倾向等结果。未发现有实质性危害的研究。我们还识别了另外17项关于价值观和偏好的研究以及1项提供成本数据的研究;数据表明性别确认激素是可接受且可负担得起的。
现有证据表明,性别确认激素可能改善关键结果,包括心理健康和生活质量,且无实质性危害的证据。来自前瞻性对照研究的进一步证据可能会提高对这些发现的信心。
世界卫生组织,通过埃尔顿·约翰艾滋病基金会和比尔及梅琳达·盖茨基金会的赠款。